Chen Yu Hua, Pallant Celeste, Sampson Christopher J, Boiti Alessia, Johnson Sabine, Brazauskas Pijus, Hardwicke Philip, Marongiu Michela, Marinova Vanesa M, Carmo Marlene, Sweeney Nathan P, Richard Ashkenaz, Shillings Anthony, Archibald Peter, Puschmann Eva, Mouzon Bernadette, Grose David, Mendez-Tavio Miriam, Chen Mao Xiang, Warr Stephen R C, Senussi Tarik, Carter Paul S, Baker Sean, Jung Cindy, Brugman Martijn H, Howe Steven J, Vink Conrad A
GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Mol Ther Methods Clin Dev. 2020 Aug 14;19:47-57. doi: 10.1016/j.omtm.2020.08.011. eCollection 2020 Dec 11.
Stable suspension producer cell lines for the production of vesicular stomatitis virus envelope glycoprotein (VSVg)-pseudotyped lentiviral vectors represent an attractive alternative to current widely used production methods based on transient transfection of adherent 293T cells with multiple plasmids. We report here a method to rapidly generate such producer cell lines from 293T cells by stable transfection of a single DNA construct encoding all lentiviral vector components. The resulting suspension cell lines yield titers as high as can be achieved with transient transfection, can be readily scaled up in single-use stirred-tank bioreactors, and are genetically and functionally stable in extended cell culture. By removing the requirement for efficient transient transfection during upstream processing of lentiviral vectors and switching to an inherently scalable suspension cell culture format, we believe that this approach will result in significantly higher batch yields than are possible with current manufacturing processes and enable better patient access to medicines based on lentiviral vectors.
用于生产水疱性口炎病毒包膜糖蛋白(VSVg)假型慢病毒载体的稳定悬浮生产细胞系,是目前广泛使用的基于用多个质粒瞬时转染贴壁293T细胞的生产方法的一种有吸引力的替代方法。我们在此报告一种通过稳定转染编码所有慢病毒载体成分的单个DNA构建体,从293T细胞快速生成此类生产细胞系的方法。所得的悬浮细胞系产生的滴度与瞬时转染所能达到的滴度一样高,可以很容易地在一次性搅拌罐生物反应器中扩大规模,并且在延长的细胞培养中在遗传和功能上是稳定的。通过在慢病毒载体的上游加工过程中消除对高效瞬时转染的需求,并转向本质上可扩展的悬浮细胞培养形式,我们相信这种方法将产生比当前制造工艺更高的批次产量,并使患者能够更好地获得基于慢病毒载体的药物。